Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial

Reuters2026/08/13 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sagimet won FDA IND clearance for a Phase 3 U.S. trial of denifanstat in moderate-to-severe acne.
FDA issued a “Study May Proceed” letter; trial initiation remains targeted for 2H 2026.
Study aims to enroll about 800 patients ages 12+, randomized 2:1 to denifanstat 50 mg or placebo for 12 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9809277) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial

You may also like

Crypto prices